What Research Shows About Semaglutide and Alcohol Consumption A retrospective analysis from 2024 examined patient-reported alcohol use before and during semaglutide therapy for weight loss
Novo Nordisk Patient Assistance Program Novo Nordisk, the maker of Ozempic, offers a patient assistance program (PAP) for individuals who qualify based on income and insurance status
Jan/Feb 2026 PharmaTimes Magazine 24-25 // GLP-1 // The GLP-1 inflection point is a moment of reckoning for us all Ozempic
Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II
However, worries about too much reliance on GLP-1 drugs have resulted in 'Sell' ratings for some rivals from analysts like UBS, showing how the sector is split by strategic execution and the breadth of company portfolios.
Dose titration represents the most important preventative strategy